Skip to main content
Premium Trial:

Request an Annual Quote

Harvard Bioscience Shares Sink on Weak Genomic Solutions Results

This article has been updated to include share prices and details.

NEW YORK, Oct. 29 (GenomeWeb News) - Shares in Harvard Bioscience were down more that 8 percent to $3.74 in late-afternoon trade today after the company said poor performance from its Genomic Solutions unit acted as ballast on third-quarter revenue.

The company also lowered by $2.2 million its revenue outlook for the fourth quarter. However, Harvard said that increased product sales in its core product lines helped it report a modest gain in total revenue.

Receipts for the quarter ended Sept. 30 totaled $23.2 million, up from $21.1 million during the same period a year ago. HBIO said it is seeing strong growth in some its core product lines, such as animal physiology products, cell-biology products, and plate readers.

"However, the revenue trend at Genomic Solutions continues to track lower than we expected," CEO Chane Graziano said in a statement. Revenue for that business segment fell 29 percent year over year, and accounted for around 25 percent of total revenue for Harvard Bio.


R&D costs increased to $1.9 million in the quarter from $1.6 million during the year-ago quarter.


Harvard Bioscience had a net income of $957,000, or $.03 per share, compared to $986,000, or $.03 per share, during the same quarter last year.


As of Sept. 30, Harvard Bioscience had cash and cash equivalents of $11.6 million.

The Scan

Myotonic Dystrophy Repeat Detected in Family Genome Sequencing Analysis

While sequencing individuals from a multi-generation family, researchers identified a myotonic dystrophy type 2-related short tandem repeat in the European Journal of Human Genetics.

TB Resistance Insights Gleaned From Genome Sequence, Antimicrobial Response Assays

Researchers in PLOS Biology explore M. tuberculosis resistance with a combination of sequencing and assays looking at the minimum inhibitory concentrations of 13 drugs.

Mendelian Disease Genes Prioritized Using Tissue-Specific Expression Clues

Mendelian gene candidates could be flagged for further functional analyses based on tissue-specific transcriptome and proteome profiles, a new Journal of Human Genetics paper says.

Single-Cell Sequencing Points to Embryo Mosaicism

Mosaicism may affect preimplantation genetic tests for aneuploidy, a single-cell sequencing-based analysis of almost three dozen embryos in PLOS Genetics finds.